Foghorn Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FHTX research report →
Range $2 – $5
Price Chart
About the company
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system.
- CEO
- Adrian H. Gottschalk
- IPO
- 2020
- Employees
- 106
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on FHTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $103.14M
- P/E
- 24.57
- PEG
- 0.19
- P/S
- 0.92
- P/B
- 0.00
- EV/EBITDA
- 6.12
- Div Yield
- 0.00%
- Gross Margin
- 99.07%
- Op Margin
- 5.94%
- Net Margin
- 8.40%
- ROE
- -14.17%
- ROIC
- 4.23%
Latest fiscal year · YoY change
- Revenue
- $30.91M+36.8%
- Gross Profit
- $27.58M+22.0%
- Op Income
- $-82,107,000
- Net Income
- $-74,283,000+14.2%
- EPS
- $-1.18+25.3%
- OCF Growth
- +14.2%
- FCF Growth
- +15.0%
- 52W High
- $7.61
- 52W Low
- $1.66
- 50D MA
- $2.55
- 200D MA
- $4.43
- Beta
- 3.21
- RSI (14)
- 34
- Avg Volume
- 837.63K
No earnings-call transcripts are available for FHTX yet.
- Free Float
- 43.6%
- Shares Outstanding
- 59.96M
- Float Shares
- 26.15M
of shares held by institutions
105 13F filers
Buy/sell ratio 5.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Flagship Pioneering, LLC | 12.67M | 0 |
| Bvf Inc/Il | 5.84M | 0 |
| Fmr LLC | 5.55M | ▼ 159.61K |
| Deerfield Management Company, L.P. | 4.39M | 0 |
| Blackrock, Inc. | 3.07M | ▲ 438.40K |
| Raymond James Financial Inc | 2.48M | ▼ 10.36K |
| Vanguard Group Inc | 1.93M | ▲ 29.54K |
| Vanguard Capital Management LLC | 1.59M | ▲ 91.61K |
| Euclidean Capital LLC | 1.57M | 0 |
| Geode Capital Management, LLC | 861.65K | ▼ 49.21K |
| Siren, L.L.C. | 720.72K | 0 |
| State Street Corp | 692.29K | ▼ 5.18K |
Held by 118 ETFs
Biggest fund positions in FHTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
| Oct 1, 26 | BVF PARTNERS L P/IL | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FHTX coverage
Recent articles, reports, and earnings notes.
No research on FHTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FHTX report →INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
prnewswire.com · Nov 12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
globenewswire.com · Nov 10
Foghorn Therapeutics Inc. (FHTX) Q3 Earnings and Revenues Beat Estimates
zacks.com · Nov 9
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
globenewswire.com · Nov 9
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
prnewswire.com · Nov 5
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
globenewswire.com · Nov 3
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
globenewswire.com · Nov 3
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
prnewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.